- Home
- ELAB vs JAGX Comparison
ELAB vs JAGX Comparison
Compare ELAB & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- JAGX
- Stock Information
- Founded
- ELAB 2020
- JAGX 2013
- Country
- ELAB United States
- JAGX United States
- Employees
- ELAB N/A
- JAGX N/A
- Industry
- ELAB
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- JAGX Health Care
- Exchange
- ELAB Nasdaq
- JAGX Nasdaq
- Market Cap
- ELAB 3.2M
- JAGX 3.4M
- IPO Year
- ELAB 2023
- JAGX N/A
- Fundamental
- Price
- ELAB $2.28
- JAGX $2.24
- Analyst Decision
- ELAB
- JAGX Strong Buy
- Analyst Count
- ELAB 0
- JAGX 1
- Target Price
- ELAB N/A
- JAGX $60.00
- AVG Volume (30 Days)
- ELAB 180.3K
- JAGX 99.7K
- Earning Date
- ELAB 08-13-2025
- JAGX 08-12-2025
- Dividend Yield
- ELAB N/A
- JAGX N/A
- EPS Growth
- ELAB N/A
- JAGX N/A
- EPS
- ELAB N/A
- JAGX N/A
- Revenue
- ELAB N/A
- JAGX $11,552,000.00
- Revenue This Year
- ELAB N/A
- JAGX $22.41
- Revenue Next Year
- ELAB N/A
- JAGX $30.00
- P/E Ratio
- ELAB N/A
- JAGX N/A
- Revenue Growth
- ELAB N/A
- JAGX 13.93
- 52 Week Low
- ELAB $1.95
- JAGX $2.19
- 52 Week High
- ELAB $660.80
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- ELAB 48.70
- JAGX 29.03
- Support Level
- ELAB $2.20
- JAGX $2.32
- Resistance Level
- ELAB $2.47
- JAGX $2.79
- Average True Range (ATR)
- ELAB 0.21
- JAGX 0.14
- MACD
- ELAB 0.00
- JAGX 0.08
- Stochastic Oscillator
- ELAB 14.08
- JAGX 8.33
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.